Prediction of the Risk of Biochemical Relapse After Radical Prostatectomy for Prostate Cancer Using Radomics on Pre-therapeutic MRI
PREBOP
1 other identifier
observational
195
1 country
2
Brief Summary
With 50% of post-operative biochemical failure, efficient predictive models are needed to guide post-operative management. Radiomic features are quantitative features extracted from medical imaging, supposed to be correlated with tumor heterogeneity. We aim to build and test three predictive models (clinical, radiomic and combined models).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2018
Shorter than P25 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 26, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 28, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
August 28, 2018
CompletedFirst Submitted
Initial submission to the registry
August 19, 2019
CompletedFirst Posted
Study publicly available on registry
August 21, 2019
CompletedSeptember 12, 2019
August 1, 2019
2 months
August 19, 2019
September 11, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Prediction of biochemical failure
Comparison of AUCs between each predictive model
From the date of surgery until data collection (up to 100 months)
Secondary Outcomes (1)
Prediction of survival without biochemical failure
From the date of surgery until data collection (up to 100 months)
Eligibility Criteria
\- Patients with high-risk prostate cancers who underwent pre-operative prostate MRI followed by radical prostatectomy +/- lymphadenectomy
You may qualify if:
- Age \> 18yo
- Patients underwent radical prostatectomy
- High-risk prostate cancers: at least 1 criteria (pt3a/pT3b/pT4, R1, Gleason score \> 7)
You may not qualify if:
- No available pre-operative MRI
- No analyzable pre-operative MRI
- proof of lymph-node involvement (cN1/2 or pN1/2)
- post-operative PSA \> 0.04ng/mL
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
CHRU de Brest
Brest, Brittany Region, 29609, France
Centre Hospitalier de Cornouaille
Quimper, Brittany Region, 29000, France
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 19, 2019
First Posted
August 21, 2019
Study Start
June 26, 2018
Primary Completion
August 28, 2018
Study Completion
August 28, 2018
Last Updated
September 12, 2019
Record last verified: 2019-08
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- Data will be available beginning one year and ending following the publication
- Access Criteria
- Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.
All collected data that underlie results in a publication